MYRIAD ONCOLOGY
Live / Allowed — Notice of allowance issued (as of 17 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 06 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99070993
- Mark type
- Stylized text
- Filed
- 06 Mar 2025
- Published for opposition
- 20 Jan 2026
- Attorney of record
- Katherine P. Califa
Goods and services
- Class 010 — Medical apparatus: Medical test kit related to oncology comprising specimen collection containers in the nature of tubes for the collection of bodily fluids containing cell-free DNA, printed instructions and test forms, materials for transmitting specimens in the nature of envelopes, cardboard boxes, and plastic bags all in the medical field, and printed user information inserts being forms
- Class 041 — Education and entertainment services: Providing online publications, namely, questionnaires for medical screening for diagnostic or treatment purposes
- Class 042 — Scientific and technological services: Providing temporary use of non-downloadable software for use in medical screening for diagnostic or treatment purposes; Software as a service (SAAS) services featuring software for use in medical screening for diagnostic or treatment purposes
- Class 044 — Medical, beauty and agricultural services: Medical testing services related to oncology; genetic and genomic testing related to oncology for medical purposes; genetic testing for medical purposes; genetic testing services for diagnostic or treatment purposes; genetic counseling; medical diagnostic testing, monitoring, and reporting services; providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing for the detection of cancer to assess the presence or absence of residual disease; health assessment services; providing personalized healthcare and medical information, namely, providing medical information and reports; providing medical information, consultancy and advisory services; health evaluation services, namely, performing health assessments and health screening for purposes of determining medical risks and further testing
Owner
- Myriad Genetics, Inc., Salt Lake City, UT, US
- Myriad Genetics, Inc., Salt Lake City, UT, US
Prior registrations
Prosecution history
- 17 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 Jan 2026 — PUBLISHED FOR OPPOSITION
- 14 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Dec 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 09 Oct 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 09 Oct 2025 — FINAL REFUSAL E-MAILED
- 09 Oct 2025 — FINAL REFUSAL WRITTEN
- 24 Sept 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Sept 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Sept 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 25 Jun 2025 — NOTIFICATION OF PRIORITY ACTION E-MAILED